INS and amyloidosis: On the other hand, subcutaneous applications of insulin during the treatment of diabetes may cause insulin-derived amyloidosis characterized by the formation of insulin amyloid fibrils at the site of repeated injections (Dische et al., 1988; D'Souza et al., 2014; Nagase et al., 2014; Nilsson, 2016).